<DOC>
	<DOCNO>NCT02969382</DOCNO>
	<brief_summary>A study evaluate efficacy safety experimental drug ( SEP-363856 ) acutely psychotic adult schizophrenia</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety SEP-363856 Acutely Psychotic Adults With Schizophrenia</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , parallel-group , flexibly-dosed , study evaluate efficacy safety SEP-363856 acutely psychotic adult subject schizophrenia use SEP-363856 ( 50 75 mg/day [ ie , daily ] ) versus placebo 4-week treatment period . Primary hypoathesis test : H0 : μSEP = μPBO versus H1 : μSEP ≠ μPBO , μSEP μPBO mean change Baseline Week 4 PANSS total score SEP-363856 placebo arm , respectively . Subjects complete study SEP361-201 may eligible enroll open-label extension study SEP361-202 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Subject must give write informed consent privacy authorization prior participation study . 2 . Subject must willing able comply study procedure visit schedule , include require hospitalization washout period doubleblind treatment period , must able understand follow verbal write instruction . 3 . Male female subject 18 40 year age ( inclusive ) time consent . 4 . Subject meet DSM5 criterion primary diagnosis schizophrenia establish clinical interview ( use DSM5 reference confirm use SCIDCT ) . The duration subject 's illness whether treat untreated must ≥ 6 month . 5 . Subject must CGIS score ≥ 4 ( moderate great ) screen Baseline . 6 . Subject must PANSS total score ≥ 80 PANSS subscale score ≥ 4 ( moderate ) 2 follow PANSS subscale item : delusion , conceptual disorganization , hallucination , unusual thought content screen Baseline . 7 . Subject acute exacerbation psychotic symptom ( longer 2 month ) mark deterioration function Baseline ( history ) subject hospitalize purpose treat acute psychotic exacerbation 2 consecutive week less immediately screen . Subjects hospitalize 2 week reason unrelated acute exacerbation include concurrence Medical Monitor hospitalization acute relapse . For example , subject longterm hospital set acute exacerbation transfer acute unit eligible study . 8 . Subject 2 prior hospitalization treatment acute exacerbation schizophrenia ( include current hospitalization ) . 9 . Subject 's BMI must least 18 kg/m2 35 kg/m2 . 10 . Female subject must negative serum pregnancy test screening . 11 . Female subject reproductive potential agrees remain abstinent use adequate reliable contraception throughout study least 30 day last dose study drug take . In Investigator 's judgment , subject adhere requirement . 1 . Adequate contraception define continuous use either two barrier method ( eg , condom spermicide diaphragm spermicide ) hormonal contraceptive . Acceptable hormonal contraceptive include follow : ) contraceptive implant ( Norplant® ) implant least 90 day prior screen ; b ) injectable contraception ( medroxyprogesterone acetate injection ) give least 14 day prior screen ; c ) oral contraception take direct least 30 day prior screen . 2 . Subjects nonreproductive potential , ie , subject surgically sterile , undergone tubal ligation , postmenopausal ( define least 12 month spontaneous amenorrhea 6 12 month spontaneous amenorrhea follicle stimulate hormone ( FSH ) concentration within postmenopausal range determine laboratory analysis ) require remain abstinent use adequate contraception . 12 . Male subject female partner ( ) childbearing potential must agree avoid father child use acceptable method birth control screen least 30 day last study drug administration . 13 . Subject must able agree remain prior antipsychotic medication duration study . 14 . Subject must total score &lt; 5 SAS Baseline ( Day 1 ) . 15 . Subject , opinion Investigator , generally healthy base screen medical history , PE , neurological examination , vital sign , clinical laboratory value ( hematology , serum chemistry , urinalysis , lipid panel , coagulation panel , thyroid panel , serum prolactin ) . 16 . Subject stable living arrangement time screen agrees return similar living arrangement discharge . This criterion mean exclude subject temporarily leave stable living arrangement ( eg , due psychosis ) . Such subject remain eligible participate protocol . Chronically homeless subject enrol . 17 . Subject must agree comply restriction require length time 1 . Subject answer `` yes '' `` Suicidal Ideation '' Item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) CSSRS assessment Screening ( ie , past one month ) Baseline ( ie , since last visit ) . 2 . Subject tolerate venipuncture poor venous access would cause difficulty collect blood sample . 3 . Subject currently participate , participate , study investigational market compound device within 6 month prior sign inform consent , participate 2 study within 24 month prior sign inform consent . 4 . Subject previously receive SEP363856 . 5 . Subject clinically significant unstable medical condition clinically significant chronic disease opinion Investigator , would limit subject 's ability complete and/or participate study : 1 . Hematological ( include deep vein thrombosis ) bleeding disorder , renal , metabolic , endocrine , pulmonary , gastrointestinal , urological , cardiovascular , hepatic , neurologic , allergic disease ( except untreated , asymptomatic , seasonal allergy time dose ) . 2 . History cancer significant neoplasm . 3 . Disorder history condition , previous gastrointestinal surgery ( eg , cholecystectomy , vagotomy , bowel resection , surgical procedure ) may interfere drug absorption , distribution , metabolism , excretion , gastrointestinal motility , pH , clinically significant abnormality hepatic renal system , history malabsorption . 4 . Subject Alcohol Substance Abuse Disorder ( DSM5 criterion ) . The exception include caffeine nicotine . 5 . Subject clinically significant abnormal 12lead ECG may jeopardize subject 's ability complete study screen 12lead ECG demonstrate one following : heart rate &gt; 100 beat per minute , QRS &gt; 120 m , QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m ( male ) , QTcF &gt; 470 m ( female ) , PR &gt; 220 ms. 6 . Subjects know history human immunodeficiency virus ( HIV ) seropositivity 6 . Female subject pregnant lactating . 7 . Subject lifelong history presence symptom consistent major psychiatric disorder primary schizophrenia define DSMV unless symptom rediagnosed consistent primary schizophrenia . Exclusionary disorder include limited alcohol use disorder ( within past 12 month ) , substance ( nicotine caffeine ) use disorder within past 12 month , major depressive disorder , bipolar depression , mania , schizoaffective disorder , obsessive compulsive disorder , posttraumatic stress disorder . Previous current symptom mild moderate mood dysphoria anxiety allow long symptoms focus primary treatment . 8 . Subject test positive drug abuse screening , however , positive test amphetamine , barbiturate , opiate , benzodiazepine may result exclusion subject investigator determines positive test result prescription medicine ( ) . In event subject test positive cannabinoids ( tetrahydrocannabinol ) , Investigator evaluate subject 's ability abstain use substance study . This information discuss Medical Monitor prior study enrollment . 9 . Subject significant risk harm him/herself others accord Investigator 's judgment . 10 . Subject attempt suicide within 3 month prior screen 11 . Subject involuntarily hospitalize . 12 . Subject receive depot antipsychotic unless last injection least one treatment cycle least 30 day ( whichever longer ) , prior screen phase . 13 . Subject consider resistant antipsychotic treatment Investigator , define failure respond 2 market antipsychotic agent , give adequate dose least 4 week ( 28 day ) within 1 year ( 365 day ) Screening ( eg , subject hospitalize worsen psychotic symptom due insufficient clinical response require frequent use antipsychotic drug temporary basis ) . 14 . Subject history treatment clozapine refractory psychosis and/or subject treat clozapine ( reason ) within 4 month Screening . 15 . Subject receive total dose antipsychotic medication equivalent &gt; 12.0 mg/day haloperidol Screening . 16 . Subject receive electroconvulsive therapy treatment within 3 month prior screen expect require ECT study . 17 . Subject take take disallowed recent concomitant medication . Subjects must taper antipsychotic medication Day 1 18 . Subject history allergic reaction medication know suspected sensitivity substance contain formulation . 19 . Subject past episode significant extrapyramidal symptom ( EPS ) current medication require dose modification addition antiParkinson 's treatment within last 6 month . 20 . Subject clinically significant abnormal laboratory value ( hematology , serum chemistry , urinalysis , lipid panel , coagulation panel , thyroid panel , serum prolactin ( Note : abnormal finding may clinically significant questionable significance discuss Medical Monitor prior include subject ) . 21 . Subject demonstrate evidence acute hepatitis , clinically significant chronic hepatitis evidence clinically significant impaired hepatic function clinical laboratory evaluation . Note : Subjects serum alanine transaminase ( ALT ) aspartate transaminase ( AST ) level ≥ 3 time upper limit reference range provide central laboratory require retesting . If retesting , laboratory value remain ≥ 3 time upper limit , subject exclude . 22 . Subject serum blood urea nitrogen ( BUN ) serum creatinine ( Cr ) value ≥ 1.5 time upper limit normal reference range . 23 . Subject experience significant blood loss ( ≥ 473 mL ) donate blood within 60 day prior first dose study drug ; donate plasma within 72 hour prior first dose study drug intend donate plasma blood undergo elective surgery study participation within 60 day last study visit . 24 . Subject use disallow prescription disallow nonprescription drug , vitamin , dietary herbal supplement within 14 day prior dose anticipates need disallow medication participation study [ exception : female subject take oral , patch , intrauterine device ( IUD ) hormonal contraceptive , progestin implant injection ] .. 25 . Subject staff member relative staff member . 26 . Subject opinion Investigator , unsuitable way participate study . 27 . Subjects fast blood glucose screen ≥ 126 mg/dL ( 7.0 mmol/L ) HbA1c ≥ 6.5 % exclude . 28 . Subject prolactin concentration &gt; 100 ng/mL screen history pituitary adenoma . Randomization criteria 1 . Subject must PANSS total score ≥ 80 Baseline ( Day 1 ) . 2 . Subject must PANSS subscale score ≥ 4 2 follow PANSS subscale item : delusion , conceptual disorganization , hallucination , unusual thought content Baseline ( Day 1 ) . 3 . Subject must CGIS score ≥ 4 Baseline ( Day 1 ) . 4 . Subject must total score &lt; 5 SAS Baseline ( Day 1 ) . 5 . Subject must answer `` yes '' `` Suicidal Ideation '' Item 4 ( active suicidal ideation intent act , without specific plan ) Item 5 ( active suicidal ideation specific plan intent ) CSSRS assessment Baseline ( ie , since last visit ) . 6 . Subject must meet inclusion none exclusion criterion Baseline ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>